MeSH D008269 - macular edema
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Roche | Faricimab | Vabysmo |  | 2022-09-15 | $2,221.9 M | Q4/22-Q3/23 |
| AbbVie | Dexamethasone | Ozurdex |  | 2010-07-26 | $488 M | Q2/23-Q1/24 |
| Novartis | Ranibizumab | Lucentis |  | 2007-01-22 | $1,848 M | Q2/20-Q2/23 |
| Sanofi | Aflibercept | Zaltrap |  | 2012-08-03 |  |  |
| Bayer | Aflibercept | Eylea |  | 2012-11-21 |  |  |
1
2
>
Clinical Trials
Historical Success Rate
Phase 1
79%27/34
Phase 2
47%28/60
Phase 3
63%27/43
Approved: 9Overall Success rate: 23%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
>
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use